# A Study to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents

> **NCT04530110** · PHASE3 · COMPLETED · sponsor: **Teva Branded Pharmaceutical Products R&D LLC** · enrollment: 506 (actual)

## Conditions studied

- Migraine

## Interventions

- **DRUG:** Fremanezumab

## Key facts

- **NCT ID:** NCT04530110
- **Lead sponsor:** Teva Branded Pharmaceutical Products R&D LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-16
- **Primary completion:** 2025-08-15
- **Final completion:** 2025-12-22
- **Target enrollment:** 506 (ACTUAL)
- **Last updated:** 2026-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04530110

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04530110, "A Study to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04530110. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*